Prolonged glucosuria and relapse of diabetic ketoacidosis related to SGLT2‐inhibitor therapy

Prolonged glucosuria and relapse of diabetic ketoacidosis related to SGLT2‐inhibitor therapy

Abstract SGLT2 inhibitors (SGLT2i) are glucose‐lowering medications which increase the renal threshold for glucose reabsorption and promote glucosuria. Treatment with these agents raises serum ketone levels, and cases of diabetic ketoacidosis (DKA) during therapy have been reported. The duration of...

Full description

Bibliographic Details
Main Authors: Gregory P. Westcott, Alissa R. Segal, Joanna Mitri, Florence M. Brown
Format: Article
Language:English
Published: Wiley 2020-04-01
Series:Endocrinology, Diabetes & Metabolism
Subjects:
diabetic ketoacidosis
inpatient diabetes management
prolonged glucosuria
SGLT2 inhibitors
Online Access:https://doi.org/10.1002/edm2.117
Description
Summary:Abstract SGLT2 inhibitors (SGLT2i) are glucose‐lowering medications which increase the renal threshold for glucose reabsorption and promote glucosuria. Treatment with these agents raises serum ketone levels, and cases of diabetic ketoacidosis (DKA) during therapy have been reported. The duration of glucosuria and inpatient course of SGLT2i‐related DKA, however, is not well‐characterized. We report 11 inpatient cases of SGLT2i‐related DKA, including a subset of patients who experienced prolonged glucosuria and relapse of DKA during their hospitalization.
ISSN:2398-9238

Similar Items